Vasculitis Clinical Trials

20 recruiting

Vasculitis Trials at a Glance

72 actively recruiting trials for vasculitis are listed on ClinicalTrialsFinder across 6 cities in 30 countries. The largest study group is Phase 1 with 17 trials, with the heaviest enrollment activity in Philadelphia, Cleveland, and Paris. Lead sponsors running vasculitis studies include China Immunotech (Beijing) Biotechnology Co., Ltd., University of Pennsylvania, and Assistance Publique - Hôpitaux de Paris.

Browse vasculitis trials by phase

Treatments under study

About Vasculitis Clinical Trials

Looking for clinical trials for Vasculitis? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Vasculitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Vasculitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 72 trials

Recruiting
Phase 3

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

Vasculitis
Amgen20 enrolled31 locationsNCT06321601
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled18 locationsNCT06308978
Recruiting
Phase 4

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Amgen300 enrolled76 locationsNCT06072482
Recruiting

The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions

VasculitisSystemic Lupus Erthematosus (SLE)Rheumatic Diseases+3 more
McGill University Health Centre/Research Institute of the McGill University Health Centre100 enrolled1 locationNCT07278609
Recruiting
Phase 1

Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube

Diffuse Alveolar HemorrhageAntineutrophil Cytoplasmic Antibody Positive Vasculitis
Mayo Clinic6 enrolled1 locationNCT07556484
Recruiting
Phase 3

BDB-001 Phase III Trial in ANCA-Associated Vasculitis

ANCA Associated Vasculitis (AAV)
Staidson (Beijing) Biopharmaceuticals Co., Ltd300 enrolled60 locationsNCT07168161
Recruiting
Phase 2

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.75 enrolled78 locationsNCT07160608
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting

Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting

AsthmaVasculitisInflammatory Disease+2 more
Imperial College London120 enrolled1 locationNCT05012033
Recruiting

Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases

Inflammatory Bowel DiseasesSclerodermaVasculitis+2 more
University Hospital, Toulouse3,000 enrolled1 locationNCT05251415
Recruiting
Phase 3

Study of Ravulizumab in Pediatric Participants With Primary IgAN

Immunoglobulin A NephropathyIgANIgA Vasculitis+3 more
Alexion Pharmaceuticals, Inc.24 enrolled14 locationsNCT07024563
Recruiting
Phase 1

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus ErythematosusLupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07236762
Recruiting
Phase 1

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled2 locationsNCT07236801
Recruiting
Phase 1

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07104721
Recruiting
Phase 1

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren&#39;s Syndrome (SS)+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07123519
Recruiting
Early Phase 1

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Rheumatoid ArthritisSystemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
Changhai Hospital60 enrolled1 locationNCT07246096
Recruiting
Phase 2

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

ANCA Associated Vasculitis (AAV)
Novartis Pharmaceuticals126 enrolled31 locationsNCT06868290
Recruiting
Phase 1

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathySystemic Sclerosis (SSc)+2 more
Therorna12 enrolled1 locationNCT07413341
Recruiting

PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis

ANCA Associated Vasculitis (AAV)
University of Edinburgh120 enrolled1 locationNCT07258524
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07305116